Analysis of Quality of Life (QOL) from the phase 3 randomized first-line indolent trial in patients with advanced follicular lymphoma receiving consolidation therapy with 90Y-ibritumomab tiuxetan
Abs.0802
Gespeichert in:
Verfasser / Beitragende:
[F. D'Amore, A. Valderrama, M. Gonzalez Diaz, N. O'Rourke, M. Petrini, C. Sebban, P.L. Zinzani, M. Gomes de Silva, N. Ketterer, A. Hagenbeek]
Ort, Verlag, Jahr:
2008
Enthalten in:
13th Congress of the European Hematology Association, 93(2008), 319
Format:
Artikel